AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE Drug Patent Profile
✉ Email this page to a colleague
When do Ammonium Chloride 0.9% In Normal Saline patents expire, and what generic alternatives are available?
Ammonium Chloride 0.9% In Normal Saline is a drug marketed by Mcgaw and is included in one NDA.
The generic ingredient in AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE is ammonium chloride. There are forty drug master file entries for this compound. Additional details are available on the ammonium chloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE?
- What are the global sales for AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE?
- What is Average Wholesale Price for AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE?
Summary for AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mcgaw | AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE | ammonium chloride | INJECTABLE;INJECTION | 006580-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Summary
Ammonium chloride 0.9% in normal saline is primarily used as an intravenous saline solution with a buffering effect to manage metabolic alkalosis and facilitate rapid volume replacement. It is not a novel drug but a well-established formulation with widespread clinical applications. Investment opportunities depend on manufacturing capacity, regulatory environment, and regional demand. Fundamentals analysis centers on the drug’s market stability, pricing, regulatory status, competitive landscape, and potential for innovation.
What Is the Market for Ammonium Chloride 0.9% in Normal Saline?
The solution is a standard intravenous infusion, particularly suited for hospitals, healthcare providers, and emergency settings. Its market size aligns with global healthcare infrastructure investments, particularly in regions with expanding inpatient care and intensive care units.
Market Size and Growth
- In 2022, the global saline solution market was valued at approximately $5.3 billion, expected to grow at a compound annual growth rate (CAGR) of 6.2% through 2027 [1].
- Ammonium chloride solutions constitute a subset within this market, mainly used in intravenous therapy for buffer and acidification purposes.
- The demand correlates with hospital admission rates, ICU occupancy, and the prevalence of conditions requiring electrolyte and acid-base management.
Regional Demand
- North America accounts for nearly 45% of the global market share owing to high healthcare expenditure and advanced infrastructure.
- Asia-Pacific shows rapid growth due to expanding healthcare systems and increasing healthcare access.
- Markets in Europe are mature with stable demand, with emerging markets in Latin America and Africa showing potential.
What Are the Fundamental Drivers and Risks?
Drivers
- Standard of Care: As a first-line solution in ICU settings, the product remains essential, especially in restructuring acid-base imbalance, where ammonium chloride provides a buffered acidifying effect [2].
- Hospital Procurement: Large-volume hospital contracts and procurement protocols sustain steady demand.
- Regulatory Status: Approved by major agencies like the U.S. FDA and EMA, facilitating manufacturing and distribution.
Risks
- Pricing Pressure: High competition and patent expiration of similar formulations could depress prices.
- Regulatory Changes: Stringent regulations or new safety guidelines could impact manufacturing and approvals.
- Alternative Treatments: Development of novel buffers, oral alternatives, or more efficient infusion solutions can reduce demand.
What Are the Key Regulatory and Manufacturing Factors?
Regulatory Environment
- Approved as a sterile injectable product in major markets; approval timelines and renewal processes maintain stability.
- Requires compliance with Good Manufacturing Practices (GMP) and periodic safety updates.
Manufacturing Considerations
- Well-established production lines exist, minimizing ramp-up costs.
- Material sourcing hinges on high-purity ammonium chloride and sterile saline solution components.
Patent and Pricing
- The formulation's patent life expired decades ago, making it a commoditized product.
- Pricing is often dictated by regional procurement systems, standard tariffs, and hospital budget constraints.
What Is the Competitive Landscape?
- The market comprises large pharmaceutical companies and regional manufacturers.
- Major players include Baxter International, Becton Dickinson, and local generics producers.
- Price competition is intense, with minimal differentiation outside of supply reliability and compliance.
What Are Potential Innovation Paths?
- Improved stability formulations or units with extended shelf life.
- Incorporation of sensors for infusion monitoring.
- Development of targeted electrolyte solutions for specific clinical conditions.
Financial Outlook and Investment Considerations
- Low-margin, high-volume product profile suggests a defensive investment with steady cash flow.
- Potential for growth in emerging markets and hospital network expansions.
- Limited upside without product differentiation or differentiation through added features.
- Regulatory risks remain manageable due to established approval paths.
Key Takeaways
- Ammonium chloride 0.9% in normal saline serves as a stable, essential component of intravenous therapy.
- Global demand aligns with hospital and ICU growth, particularly in developing regions.
- Market fundamentals are buoyed by regulatory approval, large-scale production, and steady hospital procurement.
- Competition centers on price, supply reliability, and regulatory compliance rather than innovation.
- Investment should focus on regional growth opportunities and supply chain robustness.
FAQs
1. Is Ammonium chloride 0.9% in normal saline patent protected?
No. The formulation has been off-patent for decades, making it a commoditized product with mainly generic manufacturers producing it.
2. What are the main indications for this solution?
It is used to treat metabolic alkalosis, provide acidifying therapy, and replenish electrolytes in hospital settings.
3. How does regional regulation impact market entry?
Approval processes are well-established in major markets; however, regional differences in labeling, quality standards, and procurement policies influence market access.
4. What are the key competitors in this drug segment?
Large multinationals like Baxter and Becton Dickinson along with regional generic producers. Price and supply chain reliability are primary competitive factors.
5. Are there growth opportunities in this market?
Yes. Expansion in emerging markets and hospital infrastructure development offer growth prospects, though innovation remains limited.
References
More… ↓
